-
Announcement of the National Medical Products Administration on the Release of the Good Manufacturing Practice for Medical Devices ([2025] No. 107)
2025-12-24
To strengthen the quality management of medical device manufacturing, regulate medical device manufacturing activities, promote normative development of the industry, and ensure the safety and effectiveness of medical devices for public use, the National Medical Products Administration has revised the Good Manufacturing Practice for Medical Devices in accordance with the Regulations for the Supervision and Administration of Medical Devices and the Provisions for Supervision and Administration of Medical Device Manufacturing.
-
Requirements for the Pilot Program of Electronic Labels for Cosmetics
2025-12-24
To regulate the pilot program for electronic labels for cosmetics (including toothpaste, hereinafter referred to as "cosmetics"), these Requirements are formulated in accordance with the provisions of the Regulations on Supervision and Administration of Cosmetics (hereinafter referred to as the "Regulations"), the Provisions for Registration and Filing of Cosmetics, the Provisions for Supervision and Administration of Manufacturing and Marketing of Cosmetics, the Provisions for Toothpaste Regulation, and the Measures for the Administration of Cosmetics Labels.
-
NMPA’s Opinions on Deepening the Reform of Cosmetics Regulation and Promoting High-Quality Industry Development
2025-12-22
To further coordinate high-quality development and high-level safety in the cosmetics sector, and thereby better meet the people's new expectations for a better life in the new era, the following opinions are proposed to deepen the reform of cosmetics regulation and promote the high-quality development of the cosmetics industry.
-
Policy Interpretation of the NMPA’s Opinions on Deepening the Reform of Cosmetics Regulation and Promoting High-Quality Industry Development
2025-12-22
To thoroughly implement the important instructions of General Secretary Xi Jinping on drug regulation and industrial development, further coordinate high-quality development and high-level safety in the cosmetics sector, and thereby better meet the people's new expectations for a better life in the new era, the NMPA has issued the NMPA's Opinions on Deepening the Reform of Cosmetics Regulation and Promoting High-Quality Industry Development (hereinafter referred to as the Opinions). The key points are interpreted as follows.
-
NMPA Announcement on Matters Concerning the Importation of Pre-approval Commercial-Scale Batch Products of Overseas-Marketed Drugs (No. 96, 2025)
2025-11-28
To implement the relevant requirements of the Opinions of the General Office of the State Council on Comprehensively Deepening the Reform of Regulation of Drugs and Medical Devices to Promote the High-Quality Development of the Pharmaceutical Industry (GBF [2024] No. 53), and to support the early use of innovative and clinically urgently needed drugs for the benefit of patients, the relevant matters related to the importation of pre-approval commercial-scale batches of overseas-marketed drugs are hereby announced as follows.
-
Policy Interpretation of the NMPA Announcement on Matters Concerning the Importation of Pre-Approval Commercial-Scale Batch Products of Overseas-Marketed Drugs
2025-11-28
The NMPA has conducted research to refine the relevant requirements and specific measures, and has issued the Announcement on Matters Concerning the Importation of Pre-Approval Commercial-Scale Batch Products of Overseas-Marketed Drugs (hereinafter referred to as the "Announcement"). This aims to shorten the time gap between drug approval and market supply in China, support the early use of innovative and clinically urgently needed drugs for the benefit of patients, and enhance the health and well-being of patients.